Literature DB >> 25408294

A practical approach to risk-benefit estimation in pediatric drug research.

Gideon Koren1.   

Abstract

One of the most difficult challenges in pediatric drug research is in exposing children to risk, often without a balanced chance of benefits. While the concept of risk is similar in adult research, the adult patient can decide for himself/herself on an acceptable level of risk, whereas children have to accept the decisions of their guardians. This paper attempts to put the complexities of estimating risk in pediatric drug research into their practical perspective, and to familiarize the reader with the way such processes are conducted in different parts of the world. Although there are regional differences, all authorities typically quantify risks of pediatric research in general, and drug research in particular, in three levels: those experienced in day-to-day life; risks slightly above this 'baseline' risk; and risks substantially above 'baseline risk'. Proportionally, the diligence of the ethics process depends on these levels, as well as on the potential benefits (or lack of) to the child involved in the research. Importantly, risk is context dependent, and a particular intervention may be effective or safe in one setting but not in another, based on local experience, staffing levels, and similar variabilities.

Entities:  

Mesh:

Year:  2015        PMID: 25408294     DOI: 10.1007/s40272-014-0100-6

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  11 in total

1.  The use of infants in drug research when there is no direct benefit to them: a survey of Canadian health care professionals serving on ethics committees.

Authors:  G Koren; J Litwack; D W Biggar
Journal:  CMAJ       Date:  1988-05-15       Impact factor: 8.262

2.  Perception of risk associated with asthma research procedures among adolescents, parents, and pediatricians.

Authors:  Robert D Annett; Janet L Brody; David G Scherer; Elizabeth A Perkett
Journal:  J Allergy Clin Immunol       Date:  2004-11       Impact factor: 10.793

3.  Identifying factors to minimize phlebotomy-induced blood loss in the pediatric intensive care unit.

Authors:  Stacey L Valentine; Scot T Bateman
Journal:  Pediatr Crit Care Med       Date:  2012-01       Impact factor: 3.624

Review 4.  Lumbar puncture in the neonate: challenges in decision making and interpretation.

Authors:  Lakshmi Srinivasan; Mary C Harris; Samir S Shah
Journal:  Semin Perinatol       Date:  2012-12       Impact factor: 3.300

5.  Meningitis after lumbar puncture in children with bacteremia.

Authors:  D W Teele; B Dashefsky; T Rakusan; J O Klein
Journal:  N Engl J Med       Date:  1981-10-29       Impact factor: 91.245

6.  Liver biopsy as a day-case procedure: selection and complications in 200 consecutive patients.

Authors:  D Westaby; B R MacDougall; R Williams
Journal:  Br Med J       Date:  1980-11-15

7.  A scale of valuations of states of illness: is there a social consensus?

Authors:  R Rosser; P Kind
Journal:  Int J Epidemiol       Date:  1978-12       Impact factor: 7.196

8.  Medical research in infants and children in the eighties: analysis of rejected protocols.

Authors:  G Koren; A Pastuszak
Journal:  Pediatr Res       Date:  1990-05       Impact factor: 3.756

9.  A comparative evaluation of local application of the combination of eutectic mixture of local anesthetics and capsaicin for attenuation of venipuncture pain.

Authors:  Devendra Gupta; Kamal Kishore; Sonal Rastogi; Prabhat K Singh; Anil Agarwal; Uttam Singh
Journal:  Anesth Analg       Date:  2013-02-11       Impact factor: 5.108

10.  Effect of Heparin Administration during Coronary Angiography on Vascular or Peripheral Complications: A Single-Blind Randomized Controlled Clinical Trial.

Authors:  Mohsen Gharakhani; Farzad Emami
Journal:  Iran J Med Sci       Date:  2013-12
View more
  1 in total

1.  Creating a new ethical climate for drug research in children and pregnant women.

Authors:  Doreen Matsui; Gideon Koren
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.